Yves Vanrenterghem

Overview

Best Publications

• Reduced exposure to calcineurin inhibitors in renal transplantation.

  Henrik Ekberg;Helio Tedesco-Silva;Alper Demirbas;Štefan Vítko

  2096
  Citations

• PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION

  J Grinyo;C Groth;R Pichlmayr;Sa Sadek

  1553
  Citations

• A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

  F. Vincenti;B. Charpentier;Y. Vanrenterghem;L. Rostaing

  1040
  Citations

• A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

  T van Gelder;L B Hilbrands;Yves Vanrenterghem;W Weimar

  771
  Citations

• Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients

  Bert Bammens;Pieter Evenepoel;H Keuleers;Kristin Verbeke

  520
  Citations

• The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

  Michael D. Hale;Andrew J. Nicholls;Roy E.S. Bullingham;Ronald Hené

  499
  Citations

• Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients.

  Sabina De Geest;Liesbeth Borgermans;Hilde Gemoets;Ivo Abraham;Ivo Abraham

  460
  Citations

• Prevalence and management of anemia in renal transplant recipients: a European survey

  Yves Vanrenterghem;Claudio Ponticelli;José Maria Morales;Daniel Abramowicz

  423
  Citations

• Free p-cresol is associated with cardiovascular disease in hemodialysis patients

  B.K.I. Meijers;B. Bammens;B. De Moor;K. Verbeke

  398
  Citations

• Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.

  Barry D. Kahan;Bruce A. Julian;Mark D. Pescovitz;Yves Vanrenterghem

  393
  Citations

• Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study

  Pieter Evenepoel;Kathleen Claes;Dirk Kuypers;Bart Maes

  391
  Citations

• Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation

  Henrik Ekberg;C Bernasconi;H Tedesco-Silva;S Vítko

  390
  Citations

• p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease

  Björn K.I. Meijers;Kathleen Claes;Bert Bammens;Henriette de Loor

  386
  Citations

• p -Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin

  Björn K. I. Meijers;Vicky De Preter;Kristin Verbeke;Yves Vanrenterghem

  378
  Citations

• Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients

  G. Opelz;Y. Vanrenterghem;G. Kirste;D. W.r. Gray

  338
  Citations

• Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study

  Henrik Ekberg;J Grinyó;B Nashan;Y Vanrenterghem

  326
  Citations

• Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.

  Bart D. Maes;Raymond Oyen;Kathleen Claes;Pieter Evenepoel

  312
  Citations

• Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients.

  Y. Vanrenterghem;L. Roels;T. Lerut;J. Gruwez

  297
  Citations

• Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

  J. O. Medina Pestana;J. M. Grinyo;Y. Vanrenterghem;T. Becker

  297
  Citations

• FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation.

  Helio Tedesco-Silva;Georges Mourad;Barry D Kahan;Josep Grinyo Boira

  276
  Citations